Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
7
×
glaxosmithkline
7
×
indiana blog main
indiana top stories
7
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
7
×
wisconsin top stories
biotech
clinical trials
eli lilly
gene therapy
ipo
medical devices
abbvie
allergan
amgen
biogen
bristol-myers squibb
cancer
What
bio
7
×
roundup
cancer
crispr
days
black
diamond’s
drugs
new
pharma
therapeutics
abbvie’s
ahead
alliance
allogene
appetite
august
biofourmis
biopharma
biotech
bread
bristol
bucks
busy
butter
buy
buyout
calls
cash
celebrate
chance
changing
color
companies
congress
congressional
continue
corner
day
debut
Language
unset
Current search:
glaxosmithkline
×
bio
×
" wisconsin blog main "
×
" indiana top stories "
×
fda
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More